Lipocine Inc. last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $1.5 million (+1209.2% year over year) and diluted EPS of -$0.08. It usually reports 35–49 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 17, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Feb 18, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 35–49 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2026
36 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
2
+1209.2%
|
-1
+79.1%
|
-0.08
+86.4%
|
|
Aug 4, 2026
35 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
0
-69.5%
|
-3
-18.9%
|
-0.32
+22.0%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
0
+27.2%
|
-4
-96.9%
|
-0.54
-54.3%
|
|
Feb 18, 2026
49 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
1
-67.2%
|
-2
-233.0%
|
-0.35
-212.7%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
0
|
-3
-43.6%
|
-0.59
-34.1%
|
|
Aug 5, 2025
36 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
1
+595.4%
|
-2
+28.1%
|
-0.41
+26.8%
|
|
Mar 7, 2024
67 days after quarter end
|
—
ended Dec 31, 2023
|
—
|
—
|
—
|
|
Jan 25, 2021
25 days after quarter end
|
—
ended Dec 31, 2020
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LPCN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Salt Lake City, United States
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1535955
- Former names
- MARATHON BAR CORP (until Jul 9, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.